Psychopharmacotherapy of Obsessive-Compulsive Symptoms within the Framework of Tourette Syndrome.
Obsessive-compulsive symptoms
SSRI
associated
psychopathology
comorbidity
drug treatment
neuroleptics
tic disorders.
Journal
Current neuropharmacology
ISSN: 1875-6190
Titre abrégé: Curr Neuropharmacol
Pays: United Arab Emirates
ID NLM: 101157239
Informations de publication
Date de publication:
2019
2019
Historique:
received:
31
01
2018
revised:
30
06
2018
accepted:
21
08
2018
pubmed:
29
8
2018
medline:
16
1
2020
entrez:
29
8
2018
Statut:
ppublish
Résumé
While Behavioral Therapy (BT) should be recommended as the first step in the treatment of OCD as well as TS, medication can be added for augmentation and in certain situations (e.g. family preference, BT not available or feasible) the priority may even reverse. This narrative review is given on the complexity of drug treatment in patients comorbid with obsessive-compulsive disorder (OCD) and Tourette syndrome (TS) and other tic problems. OCD with TS is a co-occurring combination of the two generally delimitable, but in detail, also overlapping disorders which wax and wane with time but have different courses as well as necessities and options of treatment. Distinct subtypes like "tic-related OCD" are questionable. Obsessive-compulsive symptoms (OCS) and tics are frequently associated (OCS in TS up to 90%, tics in OCD up to 37%). Sensory-motor phenomena like urges and just-right feelings reflect some behavioral overlap. The main additional psychopathologies are attention-deficit hyperactivity disorder (ADHD), mood problems and anxiety. Also, hair pulling disorder and skin picking disorder are related to OCD with TS. Hence, the assessment and drug treatment of its many psychopathological problems need high clinical experience, careful planning, and ongoing evaluation/adaptation. Drugs are able to reduce clinical symptoms but cannot cure the disorders, which should be treated in parallel in their own right; i.e. for OCD serotonin reuptake inhibitors (SSRI) and for TS (tics), certain antipsychotics can be successfully prescribed. In cases of OCD with tics, when OCS responds only partially, an augmentation with antipsychotics (recommended: risperidone and aripiprazole) may improve OCS as well as tics. Also, the benzamide sulpiride, an atypical antipsychotics, may be beneficial in treating the combination of OCS, tics and anxious-depressive problems. Probably, any additional psychopathologies of OCD might attenuate the effectiveness of SSRI on OCS; on the other hand, in cases of OCD with tics, SSRI may reduce not only OCS but also stress sensitivity and emotional problems and thus leading to better selfregulatory abilities, useful to improve tic suppression. In sum, some clinical guidance can be given, but there remain many uncertainties because of a scarce database for psychopharmacotherapy in OCD with TS.
Identifiants
pubmed: 30152283
pii: CN-EPUB-92617
doi: 10.2174/1570159X16666180828095131
pmc: PMC7059153
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
703-709Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Références
Front Neurosci. 2016 Sep 12;10:415
pubmed: 27672357
Dev Med Child Neurol. 2003 Oct;45(10):700-3
pubmed: 14515942
Z Kinder Jugendpsychiatr Psychother. 2013 May;41(3):163-9; quiz 170-1
pubmed: 23639924
J Child Adolesc Psychopharmacol. 2003;13 Suppl 1:S19-29
pubmed: 12880497
Neuroimage Clin. 2016 Nov 16;13:16-23
pubmed: 27909683
J Child Psychol Psychiatry. 2016 Sep;57(9):988-1004
pubmed: 27132945
J Psychiatr Res. 2007 Apr-Jun;41(3-4):332-7
pubmed: 16860338
J Clin Psychopharmacol. 1993 Oct;13(5):354-8
pubmed: 8227493
Biol Psychiatry. 2007 Feb 1;61(3):344-7
pubmed: 17241830
JAMA Psychiatry. 2015 Apr;72(4):325-33
pubmed: 25671412
BMC Psychiatry. 2014 Nov 29;14:317
pubmed: 25432131
J Neural Transm Suppl. 2005;(69):69-99
pubmed: 16355604
J Nerv Ment Dis. 1998 Apr;186(4):201-6
pubmed: 9569887
Nat Rev Dis Primers. 2017 Feb 02;3:16097
pubmed: 28150698
Front Neurosci. 2016 Sep 12;10:416
pubmed: 27672358
Int Rev Neurobiol. 2013;112:391-414
pubmed: 24295628
Rev Neurol (Paris). 2018 Apr;174(4):199-202
pubmed: 29606319
Neurosci Lett. 2006 Jul 31;403(1-2):96-9
pubmed: 16690208
Eur Child Adolesc Psychiatry. 2013 Nov;22(11):709-11
pubmed: 23568421
Int J Neuropsychopharmacol. 2015 May 04;18(9):
pubmed: 25939614
J Clin Psychiatry. 2016 Oct;77(10):e1240-e1247
pubmed: 27631146
Dan Med J. 2018 Apr;65(4):
pubmed: 29619935
J Clin Psychopharmacol. 2012 Aug;32(4):548-50
pubmed: 22722499
J Am Acad Child Adolesc Psychiatry. 2017 Apr;56(4):304-312
pubmed: 28335874
Z Kinder Jugendpsychiatr Psychother. 2018 May;46(3):246-263
pubmed: 28922069
Neuropharmacology. 2013 May;68:143-9
pubmed: 22728760
Arch Gen Psychiatry. 1994 Apr;51(4):302-8
pubmed: 8161290
Eur Child Adolesc Psychiatry. 2018 May;27(5):569-579
pubmed: 29098466
J Behav Ther Exp Psychiatry. 2015 Dec;49(Pt B):223-229
pubmed: 25843610
Eur Child Adolesc Psychiatry. 2017 Jun;26(6):681-689
pubmed: 28032202
JAMA. 2004 Oct 27;292(16):1969-76
pubmed: 15507582
Child Psychiatry Hum Dev. 2016 Feb;47(1):124-32
pubmed: 25894516
J Am Acad Child Adolesc Psychiatry. 2014 Dec;53(12):1308-16
pubmed: 25457929
Neurosci Biobehav Rev. 2016 Apr;63:239-55
pubmed: 26751711